Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Price & Analysis

Corbus Pharmaceuticals Holdings, Inc. (CRBP) fell 3.32% to USD 11.08 as of September 8, 2026 at 10:16 UTC, according to Nexqual real-time market data.

CRBP last closed at USD 11.08; the session ranged USD 11.06–11.45 on volume of 222,614 shares. Market capitalization is —, with a 52-week range of USD 7.12–20.56 (NCM). Source: Nexqual, September 8, 2026 at 10:16 UTC.

Key Statistics (as of September 8, 2026 at 10:16 UTC)

Technical Analysis (CRBP)

Nexqual's technical model rates CRBP "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 10:16 UTC.

From Corbus Pharmaceuticals Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-09)

Key Strengths & Strategy (as disclosed to the SEC)

• Pursuant to the CSPC License Agreement, we received an exclusive license to CRB-701 for the prevention and treatment of all oncology indications in the U.S., Canada, the European Union (including the European Free Trade Area), the U.K, and Australia.
• For example, aspects of our proprietary technology platform are based on unpatented trade secrets and know-how related to the manufacturing of our product candidates.
• We seek to protect our proprietary technology and processes, in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and commercial partners.
• Development of Drugs in the U.S.   FDA Approval Process   In the U.S., the FDA regulates drugs and biological products under the Federal Food, Drug, and Cosmetic Act, or FDCA, the Public Health Service Act, or PHSA, and implementing regulations.

Partnerships

• Competitors may use this publicly available information to gain knowledge regarding the progress of clinical development programs as well as clinical trial design.   Special Protocol Assessment The Federal Food, Drug, and Cosmetic Act directs the FDA to meet with sponsors, pursuant to a sponsor's written request, for the purpose of reaching agreement on the design and size of clinical trials intended to form the primary basis of an efficacy claim in a marketing application.
• We have a clinical supply agreement with CSPC to supply drug substance and drug product in support of clinical activities and we will seek to negotiate a commercial supply agreement with CSPC prior to a marketing application.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 10:16 UTC. This page is informational and not investment advice.